Cytosorbents (HQE) Ratios
0 Followers
Cytosorbents Ratios
DE:HQE's free cash flow for Q2 2026 was $-1.77M. For the 2026 fiscal year, DE:HQE's free cash flow was decreased by $-25.00K and operating cash flow was $-1.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.13 | 2.20 | 1.77 | 3.48 | 4.70 |
| Quick Ratio | 1.58 | 1.92 | 1.51 | 3.12 | 4.35 |
| Cash Ratio | 0.64 | 0.33 | 0.97 | 2.28 | 3.81 |
| Solvency Ratio | -0.17 | -0.52 | -0.91 | -1.15 | -0.87 |
| Operating Cash Flow Ratio | -1.27 | -1.47 | -1.49 | -2.91 | -1.02 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -8.66 | -259.18 | -24.55 |
| Net Current Asset Value | $ -17.64M | $ -14.66M | $ -4.28M | $ 5.90M | $ 37.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.66 | 0.57 | 0.34 | 0.29 | 0.15 |
| Debt-to-Equity Ratio | 4.93 | 2.42 | 0.79 | 0.52 | 0.22 |
| Debt-to-Capital Ratio | 0.83 | 0.71 | 0.44 | 0.34 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.74 | 0.56 | 0.10 | 0.12 | 0.00 |
| Financial Leverage Ratio | 7.48 | 4.27 | 2.29 | 1.79 | 1.43 |
| Debt Service Coverage Ratio | -1.51 | -12.56 | -10.18 | -265.38 | -36.59 |
| Interest Coverage Ratio | -5.45 | -11.76 | -202.35 | 0.00 | 0.00 |
| Debt to Market Cap | 0.42 | 0.28 | 0.10 | 0.08 | 0.00 |
| Interest Debt Per Share | 10.20 | 0.52 | 0.41 | 0.42 | 0.32 |
| Net Debt to EBITDA | -5.25 | -1.23 | -0.15 | 0.13 | 1.77 |
| Profitability Margins | |||||
| Gross Profit Margin | 71.48% | 69.92% | 70.62% | 59.77% | 72.46% |
| EBIT Margin | -16.15% | -59.03% | -96.20% | -89.04% | -56.71% |
| EBITDA Margin | -11.75% | -54.13% | -89.69% | -86.49% | -53.89% |
| Operating Profit Margin | -38.42% | -46.22% | -102.78% | -90.87% | -56.71% |
| Pretax Profit Margin | -23.20% | -62.96% | -96.70% | -97.74% | -63.07% |
| Net Profit Margin | -22.12% | -58.21% | -94.09% | -94.59% | -61.23% |
| Continuous Operations Profit Margin | -22.12% | -58.21% | -94.09% | -94.59% | -61.23% |
| Net Income Per EBT | 95.34% | 92.45% | 97.29% | 96.78% | 97.09% |
| EBT Per EBIT | 60.39% | 136.21% | 94.09% | 107.56% | 111.21% |
| Return on Assets (ROA) | -18.56% | -43.74% | -54.91% | -51.89% | -27.43% |
| Return on Equity (ROE) | -138.88% | -186.54% | -125.66% | -92.76% | -39.24% |
| Return on Capital Employed (ROCE) | -41.30% | -43.82% | -82.52% | -58.90% | -29.99% |
| Return on Invested Capital (ROIC) | -38.77% | -40.03% | -74.74% | -56.89% | -28.90% |
| Return on Tangible Assets | -20.02% | -47.49% | -59.26% | -55.76% | -28.95% |
| Earnings Yield | -20.62% | -41.83% | -59.00% | -48.58% | -13.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.91 | 4.86 | 5.13 | 6.12 | 8.87 |
| Payables Turnover | 3.68 | 3.21 | 2.40 | 8.43 | 3.94 |
| Inventory Turnover | 2.00 | 3.92 | 2.48 | 4.03 | 2.32 |
| Fixed Asset Turnover | 1.98 | 1.74 | 1.41 | 1.49 | 2.16 |
| Asset Turnover | 0.84 | 0.75 | 0.58 | 0.55 | 0.45 |
| Working Capital Turnover Ratio | 3.26 | 3.10 | 1.77 | 0.93 | 0.65 |
| Cash Conversion Cycle | 157.63 | 54.37 | 66.24 | 106.85 | 105.95 |
| Days of Sales Outstanding | 74.35 | 75.06 | 71.12 | 59.61 | 41.16 |
| Days of Inventory Outstanding | 182.33 | 93.16 | 147.10 | 90.53 | 157.47 |
| Days of Payables Outstanding | 99.05 | 113.85 | 151.97 | 43.29 | 92.68 |
| Operating Cycle | 256.68 | 168.21 | 218.22 | 150.14 | 198.63 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.98 | -0.27 | -0.48 | -0.65 | -0.32 |
| Free Cash Flow Per Share | -4.03 | -0.27 | -0.51 | -0.80 | -0.42 |
| Dividend Paid and CapEx Coverage Ratio | -75.47 | -50.74 | -23.13 | -4.37 | -3.27 |
| Capital Expenditure Coverage Ratio | -75.47 | -50.74 | -23.13 | -4.37 | -3.27 |
| Operating Cash Flow Coverage Ratio | -0.43 | -0.54 | -1.18 | -1.55 | -1.01 |
| Operating Cash Flow to Sales Ratio | -0.33 | -0.41 | -0.70 | -0.81 | -0.35 |
| Free Cash Flow Yield | -31.54% | -29.70% | -45.58% | -51.36% | -10.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.92 | -2.39 | -1.69 | -2.06 | -7.40 |
| Price-to-Sales (P/S) Ratio | 1.07 | 1.39 | 1.59 | 1.95 | 4.53 |
| Price-to-Book (P/B) Ratio | 6.74 | 4.46 | 2.13 | 1.91 | 2.90 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.17 | -3.37 | -2.19 | -1.95 | -9.93 |
| Price-to-Operating Cash Flow Ratio | -3.21 | -3.43 | -2.29 | -2.39 | -12.97 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.06 | 0.13 | -0.07 | -0.04 |
| Enterprise Value Multiple | -14.38 | -3.80 | -1.93 | -2.12 | -6.63 |
| Enterprise Value | 62.63M | 73.15M | 53.75M | 63.64M | 143.36M |
| EV to EBITDA | -14.38 | -3.80 | -1.93 | -2.12 | -6.63 |
| EV to Sales | 1.69 | 2.06 | 1.73 | 1.83 | 3.57 |
| EV to Free Cash Flow | -4.99 | -4.97 | -2.38 | -1.83 | -7.84 |
| EV to Operating Cash Flow | -5.06 | -5.07 | -2.48 | -2.25 | -10.24 |
| Tangible Book Value Per Share | 0.86 | 0.14 | 0.43 | 0.71 | 1.33 |
| Shareholders’ Equity Per Share | 1.90 | 0.20 | 0.52 | 0.81 | 1.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.05 | 0.08 | 0.03 | 0.03 | 0.03 |
| Revenue Per Share | 11.91 | 0.65 | 0.70 | 0.80 | 0.93 |
| Net Income Per Share | -2.63 | -0.38 | -0.65 | -0.75 | -0.57 |
| Tax Burden | 0.95 | 0.92 | 0.97 | 0.97 | 0.97 |
| Interest Burden | 1.44 | 1.07 | 1.01 | 1.10 | 1.11 |
| Research & Development to Revenue | 0.14 | 0.21 | 0.50 | 0.44 | 0.41 |
| SG&A to Revenue | 0.96 | 0.95 | 1.22 | 0.06 | 0.96 |
| Stock-Based Compensation to Revenue | 0.07 | 0.11 | 0.12 | 0.11 | 0.15 |
| Income Quality | 1.51 | 0.70 | 0.76 | 0.86 | 0.57 |
Currency in USD
